Last updated: July 11, 2026
Litigation summary and analysis for Bausch Health Ireland Limited v. Lupin Ltd. (1:19-cv-00626-CFC)
Bausch Health Ireland Limited (BIH) sued Lupin Ltd. in the District of Delaware under the Hatch-Waxman framework in case 1:19-cv-00626-CFC. The suit targets Lupin’s proposed generic entry of Bausch Health’s branded drug product covering the same NDA/Orange Book reference listed drug that BIH had patented. The matter is captioned as a patent-infringement dispute tied to FDA approval timing and market entry dates.
The case outcome, operative settlement terms, and the full asserted patent list are not provided in the input. Without those specifics, a complete, accurate litigation summary (claims asserted, patents-in-suit, procedural posture, claim construction rulings, trial or dismissal status, or settlement scope) cannot be produced.
What is the case caption and court for Bausch Health Ireland Limited v. Lupin Ltd. 1:19-cv-00626-CFC?
Answer:
- Court: U.S. District Court for the District of Delaware
- Case number: 1:19-cv-00626-CFC
- Parties: Bausch Health Ireland Limited (plaintiff) v. Lupin Ltd. (defendant)
What patents were asserted in Bausch Health Ireland Limited v. Lupin Ltd. (1:19-cv-00626-CFC)?
Answer:
No asserted-patent identifiers (patent numbers) are included in the provided information, so the patent estate in suit cannot be enumerated or analyzed.
Which BIH patents typically drive Hatch-Waxman litigation in Delaware?
Patent-infringement suits in this category often target one or more of:
- Orange Book-listed composition patents
- method-of-use patents
- formulation patents (salt form, polymorph, particle engineering, or stability-related composition features)
- manufacturing process patents
This case cannot be mapped to the specific BIH patent set without the docket’s “patents-in-suit” list.
What was Lupin’s FDA filing and Paragraph IV exposure in 1:19-cv-00626-CFC?
Answer:
The input does not include the NDA/ANDA number, the Orange Book reference product, the FDA approval pathway (ANDA Paragraph IV vs. other), or the date of FDA submission, so the Paragraph IV exposure cannot be tied to specific patents.
How Paragraph IV allegations usually shape Delaware litigation timing
In Delaware Hatch-Waxman cases, the asserted patents typically control:
- eligibility for the 45-month stay (if applicable and triggered)
- whether Lupin’s product design-around is alleged to infringe
- whether BIH seeks preliminary relief or expedited merits
These timing mechanics depend on the specific filing and procedural events that are not present here.
What is the procedural timeline for the dispute (filing, motions, hearings, outcomes)?
Answer:
The procedural timeline cannot be constructed from the input because it contains only the case identifier and parties. A litigation summary requires at least:
- complaint filing date
- answer and counterclaims (if any)
- claim construction schedule and rulings (if issued)
- summary judgment, dismissal, trial, or settlement dates
None of those dates or outcomes are provided.
What to look for in the docket for this case
A complete docket-based analysis normally covers:
- whether the case was stayed pending other litigation
- whether parties resolved before Markman or after claim construction
- any final judgment on infringement, invalidity, unenforceability, or non-infringement
- whether the case ended in stipulation, consent judgment, or settlement agreement
No docket content is included.
How do courts typically analyze infringement and invalidity in Hatch-Waxman suits like this?
Answer:
For composition or formulation patents, infringement analysis typically turns on:
- the generic product’s chemistry (salt/polymorph/composition composition)
- test results (dissolution, particle size, stability, impurities)
- expert claim construction and claim-element mapping
For invalidity, the typical defenses include:
- anticipation/obviousness under §§102/103
- enablement and written description under §112
- indefiniteness under §112 (if relevant)
- prosecution history estoppel depending on claim scope
A case-specific analysis requires the patents-in-suit, asserted claims, and court rulings.
What is the commercial and exclusivity impact of this litigation for Bausch and Lupin?
Answer:
The case identifier alone does not establish:
- which branded product BIH was protecting
- the Orange Book exclusivities at stake (patent term and any pediatric exclusivity)
- Lupin’s intended launch date or market segment
Without the product/NDA and the asserted-patent expiration dates, revenue exposure cannot be quantified.
What generic entry risks usually exist for Paragraph IV challengers
Generic entry risk typically depends on:
- whether a court enjoins launch during litigation
- whether an early settlement gives a launch “carve-out” date
- whether the settlement includes non-infringement positions or payment-for-delay terms
These require settlement/judgment specifics not provided.
What settlement terms, injunctions, or agreements apply in 1:19-cv-00626-CFC?
Answer:
No settlement agreement, consent judgment, injunction, or stipulation terms are included in the input. A litigation analysis cannot characterize:
- negotiated “entry date”
- permitted launch design changes
- covenant-not-to-sue scope
- royalty structures or reverse-payment content (if any)
What is the Orange Book status of the reference drug at issue?
Answer:
The input does not identify the Orange Book reference listed drug, so Orange Book status (listed patents, expiration dates, exclusivity blocks, and whether the case corresponded to specific listed patents) cannot be provided.
Key Takeaways
- Case 1:19-cv-00626-CFC is in the District of Delaware and is captioned Bausch Health Ireland Limited v. Lupin Ltd.
- A substantive patent-and-exclusivity litigation summary requires the asserted patents, FDA filing details (ANDA/NDA), and procedural outcomes. Those items are not present in the provided information, so no accurate patent estate or litigation outcome analysis can be completed.
FAQs
- What NDA/ANDA filing did Lupin challenge in 1:19-cv-00626-CFC?
- Which Bausch Health Orange Book patents were “patents-in-suit” in this Delaware action?
- Did the court issue a Markman order or any claim construction rulings in 1:19-cv-00626-CFC?
- Was there a settlement that set a generic launch date or covenant-not-to-sue scope?
- Did the case trigger or affect any 45-month stay or pediatric exclusivity window?
References
- U.S. District Court for the District of Delaware. Bausch Health Ireland Limited v. Lupin Ltd., Case No. 1:19-cv-00626-CFC. (Case identifier provided).
